Substitute for Form 1449 A & B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 1

Complete if Known				
Application Number 10/598,533				
Confirmation Number	6983			
Filing Date	September 1, 2006			
First Named Inventor	Yoshinobu YAMAZAKI			
Art Unit	1614			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	Q96716			

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date	
		Number	Kind Code ² (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		US 5,994,294		11-30-1999	Garvey et al.
		US 6,294,517	B1	09-25-2001	Garvey et al.
	••••••	US 5,932,538		08-03-1999	Garvey, et al.
		US 2004/072851	A1	04-15-2004	Shimoyama et al.
		US 2006/0018959	Al	01-26-2006	Naganuma et al.
		US 2006/0142374	A1	06 -29-20 06	Tsuru et al.
		US 2002/143007	Al	10-03-2002	Garvey, et al.

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date	Name of Patentee or	
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶
		JP 2001-28	2001-288115	A 10-16-2001	10-16-2001	Yamanouchi Pharmaceutical Co., Ltd.	Abstract
		JP	2000-247998	Α	09-12-2000	Kissei Pharmaceutical Co., Ltd.	Abstract
		WO	99/15202	A1	04-1-1999	Kissei Pharmaceutical Co., Ltd.	Abstract
	***************************************	wo	99/48530	Al	09-30-1999	Merck & Co., Inc.	English
		WO	2004/054574	Al	07-01-2004	Kissei Pharmaceutical Co., Ltd.	Abstract
		WO	2004/022538	Al	03-18-2004	Kissei Pharmaceutical Co., Ltd.	Abstract
			1				

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.			
		Shizuo YAMADA, et al.; IN VIVO Receptor Binding of Novel a ₁ -Adrenoceptor Antagonists for Treatment of Benign Prostatic Hyperplasia; Life Science, 1998, Vol. 62, Nos. 17/18, pp. 1585-1589	English		
		T. OKURA; Selective and sustained occupancy of Prostatic α ₁ -Adrenoceptors by oral administration of KMD-3213 and its plasma concentration in rats; JPP 2002, 54; No. 7, 975-982	English		
		K. AKIYAMA, et al.; Effects of KMD-3213, a Uroselective α ₁ -Adrenoceptor Antagonist, on the Tilt-Induced Blood Pressure Response in Normotensive Rats; Jpn J. Pharmacol. 90, No. 2, 131-137 (2002)	English		
	······································	Teruhisa OHASHI; Gekkan Hodanren, 1998, No. 591, pp. 57-60	No		
		Folia Pharmacologica Japonica, 2003, Vol. 121, No. 5, pp. 307-316;	English		
		Osamu ISHIZUKA; Geriatr Med, 2003, Vol. 41, No. 8, pp. 1149-1153	No		
		O. ISHIZUKA; Micturition in conscious rats with and without bladder outlet obstruction: role of spinal α ₁ -adrenoceptors; Br. J. Pharmacol., 1996, Vol. 117, No. 5, pp. 962-966	English		

Examiner Signature	 Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.